Trial Profile

A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Relapsed or Refractory T or B Cell Malignancies

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 10 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CTX 130 (Primary) ; Cyclophosphamide; Fludarabine
Indications B-cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
Focus Adverse reactions; Therapeutic Use
Acronyms COBALT-LYM
Sponsors CRISPR Therapeutics

07 Jan 2025 According to ClinicalTrials.gov this trial is Terminated as Patients to be followed up in the CRSP-ONC-LTF study
07 Jan 2025 Status changed from active, no longer recruiting to discontinued.
20 Mar 2024 Status changed from recruiting to active, no longer recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com